D-0526-2025 Class III Ongoing
FDA drug recall D-0526-2025 was initiated by Orient Pharma Co., Ltd. Yunlin Plant on Jun 11, 2025 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is ongoing. Affected quantity: 57504 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 9, 2025
- Initiation Date
- Jun 11, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 57504 bottles
Product description
Pitavastatin Tablets, 2 mg, Rx Only, 90 Tablets, Manufactured by: Orient Pharma Co., Ltd., 8 Kehu 1st Road, Huwei Chen, Yunlin, Taiwan, 63247, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054, Product of Taiwan, NDC 0480-3632-98.
Reason for recall
Failed Impurities/Degradation Specifications.
Distribution pattern
NJ
Code information
P061001, P061002, P061003, P061004, P061006 & P061007 Exp Date 07/2025; P061008, Exp Date 08/2025; P061009 & P061010 Exp Date 10/2025; P061011, P061012 & P061013 Exp Date 01/2026; P061016, P061017 & P061018, Exp Date 04/2026; P061019, Exp Date 05/2026; P061023, Exp Date 01/2027.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0526-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026